4D Pharma PLC
DelistedCIK 1830162fmd_0Y91R0685C9PANG7M49WPTFX7BManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Dec 31, 2021, 6 periods
Latest annual · FY2021
Millions- Total revenues
- 1
- Operating income
- (37)
- Net income
- (32)
- Free cash flow
- (38)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2018 to FY2021
- n/m
4D Pharma PLC financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2021 | FY2020 | Change | Source |
|---|---|---|---|---|
| Revenue | $718,000 | $690,000 | +4.1% | 20-F 2022-03-31 · proof |
| Operating income | -$37.3 million | -$35 million | 20-F 2022-03-31 · proof | |
| Net income | -$31.9 million | -$30.5 million | 20-F 2022-03-31 · proof | |
| Cash from operating activities | -$37.9 million | -$27.3 million | 20-F 2022-03-31 · proof | |
| Free cash flow | -$38.2 million | -$27.5 million | 20-F 2022-03-31 · proof | |
| Total assets | $58.8 million | $49.1 million | +19.7% | 20-F 2022-03-31 · proof |
| Total liabilities | $26.4 million | $10.1 million | +160.4% | 20-F 2022-03-31 · proof |
| Cash and cash equivalents | $21 million | $12 million | +74.9% | 20-F 2022-03-31 · proof |
- What was 4D Pharma PLC's revenue in fiscal 2021?
- 4D Pharma PLC reported revenue of $718,000 for fiscal 2021 (the year ended Dec 31, 2021), against $690,000 the year before (+4.1%). Source: the 20-F filed with the SEC on Mar 31, 2022. SEC
- What was 4D Pharma PLC's operating income in fiscal 2021?
- 4D Pharma PLC reported operating income of -$37.3 million for fiscal 2021 (the year ended Dec 31, 2021), against -$35 million the year before. Source: the 20-F filed with the SEC on Mar 31, 2022. SEC
- What was 4D Pharma PLC's net income in fiscal 2021?
- 4D Pharma PLC reported net income of -$31.9 million for fiscal 2021 (the year ended Dec 31, 2021), against -$30.5 million the year before. Source: the 20-F filed with the SEC on Mar 31, 2022. SEC
- What was 4D Pharma PLC's cash from operating activities in fiscal 2021?
- 4D Pharma PLC reported cash from operating activities of -$37.9 million for fiscal 2021 (the year ended Dec 31, 2021), against -$27.3 million the year before. Source: the 20-F filed with the SEC on Mar 31, 2022. SEC
- What was 4D Pharma PLC's free cash flow in fiscal 2021?
- 4D Pharma PLC reported free cash flow of -$38.2 million for fiscal 2021 (the year ended Dec 31, 2021), against -$27.5 million the year before. Source: the 20-F filed with the SEC on Mar 31, 2022. SEC
- What are 4D Pharma PLC's total assets?
- As of Dec 31, 2021, 4D Pharma PLC reported total assets of $58.8 million, against $49.1 million a year earlier (+19.7%). Source: the 20-F filed with the SEC on Mar 31, 2022. SEC
- What are 4D Pharma PLC's total liabilities?
- As of Dec 31, 2021, 4D Pharma PLC reported total liabilities of $26.4 million, against $10.1 million a year earlier (+160.4%). Source: the 20-F filed with the SEC on Mar 31, 2022. SEC
- What are 4D Pharma PLC's cash and cash equivalents?
- As of Dec 31, 2021, 4D Pharma PLC reported cash and cash equivalents of $21 million, against $12 million a year earlier (+74.9%). Source: the 20-F filed with the SEC on Mar 31, 2022. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1830162&period_type=annual&limit=5"Information only, not investment advice.